Spots Global Cancer Trial Database for estrogen receptor positive tumor
Every month we try and update this database with for estrogen receptor positive tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases | NCT02603679 | Early-Stage Bre... Estrogen Recept... | Paclitaxel Tamoxifen + Pal... Aromatase Inhib... Goserelin + Aro... | 18 Years - | Karolinska University Hospital | |
| Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | NCT04997798 | Breast Cancer Estrogen Recept... HER2-positive B... | Trastuzumab Pyr... | 18 Years - 75 Years | First Affiliated Hospital of Zhejiang University | |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer | NCT03503799 | Primary Invasiv... Estrogen Recept... Human Epidermal... | Observation | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer | NCT03503799 | Primary Invasiv... Estrogen Recept... Human Epidermal... | Observation | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | NCT01439282 | Estrogen Recept... Breast Cancer | eribulin mesyla... capecitabine | 18 Years - | Eisai Inc. | |
| OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk | NCT05333328 | Breast Cancer Estrogen Recept... HER2-negative B... Premenopausal B... Node-positive B... | Ovarian functio... | 20 Years - 50 Years | Gangnam Severance Hospital | |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women | NCT01266213 | Metastatic Brea... Estrogen Recept... Breast Cancer N... | Fulvestrant plu... Anastrozole plu... Goserelin | - 55 Years | Samsung Medical Center | |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | NCT03250676 | Breast Neoplasm... Breast Cancer Estrogen-recept... Cancer, Breast Breast Cancer F... Breast Adenocar... Estrogen Recept... ER Positive | H3B-6545 | 18 Years - | Eisai Inc. | |
| Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer | NCT03750396 | Breast Cancer Recurrent Breas... Stereotactic Bo... Estrogen Recept... Her2-negative T... Surgery | Surgical resect... Stereotactic bo... Radiofrequency ... | 20 Years - 75 Years | Gangnam Severance Hospital | |
| A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer | NCT04086875 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Estrogen Recept... Progesterone Re... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... | Focus Group Text Message Best Practice Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | NCT05868226 | HER2-positive B... Metastatic Canc... Metastatic Brea... Metastatic HER2-positive M... HER2 Mutation-R... HER-2 Protein O... HER2-negative B... Triple Negative... HR Positive Hormone Recepto... Estrogen Recept... Progesterone Re... Hormone Recepto... Solid Tumor Solid Tumor, Ad... Solid Carcinoma HER2 Low Breast... HER2 Low Breast... ER Positive Bre... PR-positive Bre... | ALX148 Fam-Trastuzumab... Zanidatamab Tucatinib | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer | NCT03750396 | Breast Cancer Recurrent Breas... Stereotactic Bo... Estrogen Recept... Her2-negative T... Surgery | Surgical resect... Stereotactic bo... Radiofrequency ... | 20 Years - 75 Years | Gangnam Severance Hospital | |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | NCT03870399 | Neuroendocrine ... Progesterone Re... Estrogen Recept... | Tamoxifen | 18 Years - | AC Camargo Cancer Center | |
| The MASTER Study (MAmmary Cancer STatin ER Positive Study) | NCT04601116 | Breast Cancer F... Estrogen Recept... | Atorvastatin 80... Placebo oral ta... | 18 Years - | Aarhus University Hospital | |
| The MASTER Study (MAmmary Cancer STatin ER Positive Study) | NCT04601116 | Breast Cancer F... Estrogen Recept... | Atorvastatin 80... Placebo oral ta... | 18 Years - | Aarhus University Hospital | |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | NCT03870399 | Neuroendocrine ... Progesterone Re... Estrogen Recept... | Tamoxifen | 18 Years - | AC Camargo Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
